Procept BioRobotics announce international launch of HYDROS Robotic

Procept BioRobotics (PRCT) announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia. “Many men living with BPH remain on long-term medication or delay surgery because they are concerned about potential trade-offs between symptom relief and side effects,” said Larry Wood, President & CEO, PROCEPT BioRobotics. “The HYDROS Robotic System expands international access to a clinically validated, next-generation AI-enabled robotic solution that delivers durable symptom relief while preserving quality of life. We are proud to bring this innovation to physicians and patients across the UK and to continue expanding our international footprint.”